Form 8-K · Current Report · Filed 2025-09-10
Alnylam Announces Convertible Senior Notes Offering
Alnylam Pharmaceuticals, Inc. announced the commencement of its proposed offering of $500 million convertible senior notes due 2028 to qualified institutional buyers under Rule 144A. The notes, which are senior, unsecured obligations, will accrue interest payable semi-annually and mature on September 15, 2028. Noteholders have the right to convert their notes in certain circumstances and during specified periods. The offering of the notes is subject to market conditions and there can be no assurance as to when the offering may be completed, or as to the actual size or terms of the offering. Alnylam intends to use a portion of the net proceeds from the offering to pay the cost of capped call transactions and to repurchase a portion of its existing 1.00% convertible senior notes due 2027.
- Filer
- Alnylam Pharmaceuticals Inc. ALNY · NASDAQ
- Filed
- Accession
- 0001193125-25-199686
- CIK
- 0001178670
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Other Events
Financial Statements and Exhibits
Market reaction
Close before filing
$482.13
Next session
-2.8%
Since filing
-57.4%
Latest close
$205.52
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ALNY reporting the same item, with the next session's move:
About Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc. is a pioneering biotechnology company dedicated to transforming the lives of patients through RNA interference (RNAi) therapeutics. This scientific approach allows for innovative treatments that can silence genes responsible for certain diseases, offering a unique angle on genetic therapies. Alnylam's primary focus is on developing therapeutics for genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases, contributing to redefining how these conditions are treated. The company's groundbreaking work in RNAi provides a platform for addressing otherwise untreatable or poorly managed medical conditions, positioning it as a leader in the biotechnology sector. With numerous collaborations, partnerships, and a growing pipeline of therapeutics, Alnylam plays a crucial role in advancing modern medicine and contributing to the evolving landscape of genetic therapeutics. Headquartered in Cambridge, Massachusetts, Alnylam underscores the critical intersection of innovation, medicine, and gene science in the financial and pharmaceutical markets.
Never miss another ALNY filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.